诺雷德（ICI 118,630）对前列腺癌患者垂体-性腺轴的长期有效抑制作用
Effective long-term suppression of pituitary-gonadal axis in prostatic cancer by Zoladex (ICI 118,630).
作者信息
Murphy G P, Greco J, Huben R
机构信息
Department of Urology, State University of New York, Millard Fillmore Hospital, Buffalo.
出版信息
Urology. 1987 Nov;30(5):482-3. doi: 10.1016/0090-4295(87)90387-6.
PMID:2960064
Abstract
Eleven patients with prostatic cancer maintained on monthly depot Zoladex (ICI 118,630) from 20 to 23.5 months are described. All are in clinical remission. Castrate levels of testosterone are maintained, and low levels of LH and FSH were observed. Contrary to a prior report, persistent blockage of the pituitary-gonadal axis is achieved and maintained with no detectable adverse side effects.
摘要
本文描述了11例前列腺癌患者，他们每月接受一次长效诺雷德（ICI 118,630）治疗，持续时间为20至23.5个月。所有患者均处于临床缓解状态。睾酮维持在去势水平，促黄体生成素（LH）和促卵泡生成素（FSH）水平较低。与先前的一份报告相反，垂体-性腺轴实现并维持了持续阻断，且未发现可检测到的不良副作用。
Zotero 插件